Skip to main content
Funded Studies

Validating BAG5 as a Therapeutic Target of Parkinson’s Disease

Poor handling and elimination of misfolded proteins has been identified as central in the development of Parkinson’s disease (PD). A special class of proteins within the cell called “chaperones” can assist in improving protein handling. Our project will target a chaperone inhibitor called BAG5 that we know compromises protein handling and the function of other proteins important in PD. We hope to prove that inhibiting BAG5 — thereby allowing the chaperones to do their job — will be a novel treatment option for PD.

Project Description:
We will first develop specialized molecules that specifically bind to and inhibit BAG5 activity. As a second approach, we will develop custom molecules that prevent the production of BAG5 in cells using a technology called short-hairpin RNA (shRNA)-mediated knockdown. Following this we will “package” these custom molecular tools into virus-based delivery systems used for gene therapy. This approach will allow us to specifically inhibit BAG5 in the dopamine-producing brain cells in a pre-clinical models of PD. 

Relevance to Diagnosis/Treatment of Parkinson’s Disease:
Inhibiting or knocking down BAG5 is a potentially new way slow the course of PD by preventing the degeneration of dopamine-producing neurons in the brain. 

Anticipated Outcome:
If we can inhibit BAG5 activity, our findings will inform future investigation into different therapeutic strategies (gene therapy, novel drugs) that target BAG5 activity.


  • Suneil K. Kalia, MD, PhD, FAANS, FRCS

    Toronto ON Canada

Discover More Grants

Search by Related Keywords

Within the Same Program

Within the Same Funding Year

We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.